CCTG

PA.7

NCT02879318

PA.7

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Durvalumab + Tremelimumab

Treatment Arms

o Active Comparator: Gemcitabine plus Nab-Paclitaxel

o Experimental: Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab